• Home
  • About IBT
    • Vision and Mission
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
  • Pipeline
    • IBP-9414
    • IBP-1016
  • Investors & Media
    • Shares
    • Share Issue
    • Ownership Structure
    • Presentations
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • News
    • Investors & Media Contact
  • Contact Us
IBT Logo IBT Logo
  • En
  • Sv
  • Home
  • About IBT
    • Vision and Mission
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
  • Pipeline
    • IBP-9414
    • IBP-1016
  • Investors & Media
    • Shares
    • Share Issue
    • Ownership Structure
    • Presentations
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • News
    • Investors & Media Contact
  • Contact Us

News


New CMO at IBT

Infant Bacterial Therapeutics is welcoming Erik Kinnman as Chief Medical Officer. Erik will contribute with his extensive knowledge and experience from the pharmaceutical industry to the on-going drug development program.
 
See Who we are here

August 22, 2014

Latest News

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
This site uses cookies – small text-based files that are placed on your device to help us provide a better user experience. Find out more.
Contact | info@ibtherapeutics.com
© Copyright Infant Bacterial Therapeutics AB 2019
Cookie Policy Privacy Policy Terms of Use